News
EQS-News: Alzchem Group AG approves growth investments of around EUR 120 million for additional capacity in the sports, food and health sectors
EQS-Adhoc: Alzchem Group AG: Alzchem Group AG: Investment program of around 120 million euros approved for further capacity expansion in creatine products
The Cincinnati Insurance Company Deploys Guidewire ClaimCenter to Transform Claims Operations
Guidewire (NYSE: GWRE) announced that it’s worked with The Cincinnati Insurance Company to successfully deploy Guidewire ClaimCenter to power claims management for Cincinnati’s insurance
Data I/O Announces Strengthening of Board of Directors
Data I/O Corporation (NASDAQ: DAIO), the leading global provider of data programming and security provisioning solutions for flash, flash-memory based intelligent devices and microcontrollers
Form 8.3 - The Vanguard Group, Inc.: American Axle & Manufacturing Holdings, Inc.
Form 8.3 - The Vanguard Group, Inc.: Avadel Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Greencore Group plc
Form 8.3 - The Vanguard Group, Inc.: Bluefield Solar Income Fund Limited
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
Form 8.3 - The Vanguard Group, Inc.: Dowlais Group plc
Form 8.3 - The Vanguard Group, Inc.: Empiric Student Property plc
Form 8.3 - The Vanguard Group, Inc.: Petershill Partners plc
Form 8.3 - The Vanguard Group, Inc.: Bakkavor Group plc
Form 8.3 - The Vanguard Group, Inc.: Just Group plc
Form 8.3 - The Vanguard Group, Inc.: International Personal Finance plc
Form 8.3 - The Vanguard Group, Inc.: NCC Group plc
Form 8.3 - The Vanguard Group, Inc.: Unite Group plc, The
Form 8.3 - The Vanguard Group, Inc.: Big Yellow Group plc
EQS-Adhoc: aap Implantate AG: Cash capital increase
EQS-News: JPMorgan ETFs (Ireland) ICAV: Dividend Declaration
Turkiye Garanti Bankasi A.S.: Announcement regarding Syndicated Loan Agreement
Aperam Innovation Lab introduces Grade 316A: The alternative to 316L combining performance and cost efficiency
Bayer Starts Phase IIa Study for Treatment of Patients With Alport Syndrome
Bayer announced today initiation of a Phase IIa clinical trial with BAY 3401016, an investigational monoclonal antibody with potential to block a protein called Semaphorin 3A (Sema3A), which is




